Clinical Research Directory
Browse clinical research sites, groups, and studies.
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
Sponsor: Peking University Cancer Hospital & Institute
Summary
This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell therapy.
Official title: 18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy in Patients With Lymphoma or Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-06-24
Completion Date
2028-12-31
Last Updated
2026-07-24
Healthy Volunteers
Yes
Conditions
Interventions
18F-grazy-02
18F-grazy-02 PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 18F-grazy-02 , a Total-body PET/CT uEXPLORER scanner will be applied.
Locations (1)
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China